Steroidal selective androgen receptor modulator (SARM)

YK-11

No controlled trial of YK-11 in people was identified in PubMed or ClinicalTrials.gov, and the World Anti-Doping Agency's 2026 list names YK-11 as a prohibited SARM.1

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

YK-11 after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.

Drawn from the half-life in the app's model, ~6 h. The model's figures

YK-11 is a steroidal compound that Kanno and colleagues at the Faculty of Pharmaceutical Sciences, Toho University, described in Biological and Pharmaceutical Bulletin in 2011 as a partial agonist of the androgen receptor in a reporter assay.2 The same group later reported that YK-11 induced follistatin expression in C2C12 myoblast cells (Kanno and colleagues, Biological and Pharmaceutical Bulletin, 2013).3 Thevis and colleagues at the German Sport University Cologne call it "the steroidal SARM YK-11" in a 2017 mass spectrometry study written for doping control.4

Piper and colleagues (German Sport University Cologne, Drug Testing and Analysis, 2018) write that YK11 is "an experimental drug candidate and a non-approved substance for humans" and that "scientific data on its metabolism is scarce".5 They describe a steroidal compound detected "in a seized black market product" that was identified as YK11.5 The US Food and Drug Administration states that bodybuilding products that often contain SARMs "have not been approved by the FDA", and that such products are unapproved drugs that the agency has not reviewed for safety and effectiveness.6 The same FDA page reports a laboratory test of a product named GE Labs Ykarine that confirmed YK-11 as a listed ingredient and also detected undeclared trendione, which the FDA describes as an anabolic steroid.6

The app grades the evidence for YK-11 as emerging. The sources read describe cell, rat and horse experiments, analytical chemistry work and regulator warnings, and no controlled trial in people was identified. The app lists oral as the only route for YK-11 and a typical dose of 5 to 15 mg per day, and none of the sources read gives a human dose.

In a reporter assay in cells, Kanno and colleagues describe YK-11 as a partial agonist of the androgen receptor that "accelerates nuclear translocation of AR".2 They report that it "activates AR without causing N/C interaction", which they propose may be responsible for its partially agonistic behaviour in that system.2 In MDA-MB 453 cells they describe it as a "gene-selective agonist of AR", with an effect on gene expression relative to an androgen agonist that "varies depending on the gene context".2 Their conclusion is worded cautiously: "Our results suggest that YK11 might act as selective androgen receptor modulator (SARM)".2

In C2C12 myoblast cells, Kanno and colleagues report that myogenic regulatory factors (MyoD, Myf5 and myogenin) were induced more by YK-11 than by dihydrotestosterone (DHT).3 YK-11, but not DHT, induced follistatin expression, and "the YK11-mediated myogenic differentiation was reversed by anti-Fst antibody".3 The authors write that their results suggest "the induction of Fst is important for the anabolic effect of YK11", which is a statement about cultured cells.3 The PubMed record of this 2013 paper does not mention myostatin. Piper and colleagues write that YK11 "is described to possess selective androgen receptor modulator- and myostatin inhibitor-like properties", and the sources read do not report a myostatin measurement for YK-11.5

Yatsu and colleagues (Toho University, Biological and Pharmaceutical Bulletin, 2018) report that YK-11 and DHT "accelerated cell proliferation and mineralization" in MC3T3-E1 mouse osteoblast cells.7 YK-11-treated cells increased the osteoblast markers osteoprotegerin and osteocalcin compared with untreated cells, and these observations "were attenuated by androgen receptor (AR) antagonist treatment".7 They also report that the phosphorylated Akt protein level was increased by YK-11 and DHT treatment.7

All of the findings in this section come from cultured cells.

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~6 h
Bioavailability
95%
Typical dose
5–15 mg/day
Route
Oral
Time to peak
~1.5 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics6 rows
ParameterApp's figureReported in the sources
Half-life~6 hNo half-life for YK-11 in people or animals was identified in the PubMed and ClinicalTrials.gov searches, so the app's figure has no figure from a source beside it
Bioavailability95%No oral bioavailability figure was identified; the PubMed record of an elimination study with six-fold deuterated YK11 states that, as expected, "no intact YK11 was observed" in the urine samples, and gives no route, dose or number of participants5
Time to peak~1.5 h (the app also lists a duration of about 12 h)No time to peak or duration of effect was identified in the sources read
Urinary metabolitesNot an app figureFourteen deuterated urinary metabolites (unconjugated, glucuronidated and sulfoconjugated); unconjugated ones disappeared within 24 hours after administration, while glucuronidated and sulfated ones were traceable for more than 48 hours5
Chemical stabilityNot an app figure"YK-11 is easily hydrolysed in just a few hours", from a method study of dietary supplements; the record also states that hydrolysed YK-11 under acidic conditions was confirmed by NMR, and the stated time is not a half-life in the body8
Horse plasma and urineNot an app figureAfter three daily oral doses of 50 mg in two Thoroughbred horses, parent YK-11 and seven phase I metabolites were detected in plasma and 11 phase I metabolites in urine9

Piper and colleagues note that, because of the steroidal backbone and the "arguably labile orthoester-derived moiety", "substantial metabolic conversion in vivo was anticipated".5 Their record says two glucuronidated metabolites, 5β-19-nor-pregnane-3α,17β,20-triol and 5β-19-nor-pregnane-3α,17β-diol-20-one, were confirmed by synthesis and nuclear magnetic resonance and added to an analytical method for anabolic agents.5 In horses, the most abundant analytes in urine were a mono-O-demethylated breakdown product and di-O-demethylated YK-11, and the most abundant in plasma were two isomers of the breakdown product with an additional hydroxylation.9 The app uses a one-compartment model for YK-11, and none of the sources read fits or reports a pharmacokinetic model.5

4

Human studies

No controlled trial in people was identified in PubMed or ClinicalTrials.gov. The table lists the nine studies of YK-11 among the sources read; most involve cells, animals or laboratory analysis, and the People column says so.

Table 4.1Human studies9 rows
Study and yearDesignPeopleDose and lengthMain result
Kanno and colleagues, Biological and Pharmaceutical Bulletin, 20112Laboratory reporter assay in cellsNone; MDA-MB 453 cellsNot stated in the PubMed recordPartial agonist of the androgen receptor; "gene-selective agonist of AR in MDA-MB 453 cells"2
Kanno and colleagues, Biological and Pharmaceutical Bulletin, 20133Laboratory study in cells, with an anti-follistatin antibodyNone; C2C12 myoblast cellsNot stated in the PubMed recordFollistatin induced by YK-11 but not DHT; differentiation reversed by anti-Fst antibody3
Yatsu and colleagues, Biological and Pharmaceutical Bulletin, 20187Laboratory study in cells, with an AR antagonistNone; MC3T3-E1 mouse osteoblast cellsNot stated in the PubMed recordOsteoblast proliferation, mineralization and differentiation markers increased; attenuated by AR antagonist7
Dahleh and colleagues, Journal of Steroid Biochemistry and Molecular Biology, 202310Rat experiment with four groups (control, YK11, exercise, exercise plus YK11) and a molecular docking analysisNone; male Wistar rats, group sizes not stated in the PubMed recordYK11 0.35 g/kg; five-week protocol; route not stated in the recordYK11 increased oxidative stress and impaired mitochondrial function markers in the hippocampus10
Harding and colleagues, Drug Testing and Analysis, 20239Metabolism study after oral administration, plus in vitro liver microsome incubationsNone; two Thoroughbred horsesThree daily doses of 50 mg, oralParent YK-11 and seven phase I metabolites in plasma; 11 phase I metabolites in urine; the in vitro incubations formed 79 metabolites with little overlap with the in vivo metabolism9
Piper and colleagues, Drug Testing and Analysis, 20185Elimination study with six-fold deuterated YK11; urine analysisNot stated in the PubMed record; its keywords include "human metabolism"Not stated in the PubMed recordFourteen deuterated urinary metabolites; no intact YK11 in urine5
Thevis and colleagues, Rapid Communications in Mass Spectrometry, 20174Laboratory mass spectrometry characterisationNone; chemical analysis of synthesised YK-11Not applicableDissociation pathways and diagnostic product ions identified for doping control4
Sobolevsky and colleagues, Drug Testing and Analysis, 202411Letter and case report of a doping control sampleOne doping control sample; the PubMed record has no summary textNot stated in the PubMed recordDetection of YK-11 in a doping control sample, as the title states11
Lee and colleagues, Food Additives and Contaminants Part A, 20218Method validation applied to 60 dietary supplements bought online and directly from international vendors in 2020None; products testedNot applicableMK-677 and YK-11, "not disclosed on the label", were detected in some products8

Deeper analysis: Kanno and colleagues, 2013 (follistatin in C2C12 cells)

Kanno and colleagues, from the Faculty of Pharmaceutical Sciences, Toho University, studied C2C12 myoblast cells treated with YK-11 or DHT.3 They measured key myogenic regulatory factors and follistatin expression, and tested whether an anti-follistatin antibody changed the effect.3 No animals or people were studied, and the PubMed record gives no concentrations, replicate numbers or p-values. The record states no limitations of the study. The record lists "Research Support, Non-U.S. Gov't" as a publication type, names no sponsor and lists no author tie to a company, and gives an affiliation for the first author only.3 The earlier 2011 paper by Kanno and colleagues (partial agonist in a reporter assay) likewise lists "Research Support, Non-U.S. Gov't" and no limitations.2

Deeper analysis: Piper and colleagues, 2018 (urinary metabolites)

Piper and colleagues, mainly at the Center for Preventive Doping Research, German Sport University Cologne, ran what they call an elimination study with six-fold deuterated YK11 and analysed post-administration specimens by hydrogen isotope ratio mass spectrometry coupled to single quadrupole mass spectrometry.5 They detected "Fourteen deuterated urinary metabolites", reported that no intact YK11 was observed, and found unconjugated metabolites gone within 24 hours after administration and glucuronidated and sulfated metabolites traceable for more than 48 hours.5 The PubMed record does not state how many people took part, the dose, the route or any limitations, so no pharmacokinetic parameter can be read from it. The record lists grants from the Federal Ministry of the Interior of the Federal Republic of Germany and the Manfred Donike Institute for Doping Analysis.5 Two authors list an affiliation with Bayer AG, Crop Science Division, and the record has no competing-interest statement.5 Thevis and colleagues, whose 2017 mass spectrometry study lists two authors at Bayer AG, similarly describe the work as support for doping control testing.4

Deeper analysis: Dahleh and colleagues, 2023 (rat hippocampus)

Dahleh and colleagues, at the Federal University of Pampa and the Federal University of Santa Maria in Brazil, gave male Wistar rats YK11 (0.35 g/kg), exercise (a swimming protocol), both, or neither over a five-week protocol.10 They also ran a molecular docking analysis, which they say "showed high affinity with YK11" for the androgen receptor.10 They report that YK11 increased oxidative stress and proteotoxic effects and impaired "all mitochondrial function markers in the hippocampus".10 Exercise alone "had a neuroprotective effect", and exercise plus YK11 prevented some mitochondrial toxicity markers (MnSOD/SOD2 and MTT reduction capacity) but "did not reverse YK11's neurochemical impairments".10 The authors write that their findings "highlight the need for further research to assess the safety and efficacy of YK11 and SARM use in humans".10 The PubMed record does not give group sizes, the route of administration or a limitations statement, and the findings are from rats. The record lists "Research Support, Non-U.S. Gov't" as a publication type and a statement that "The authors declare that they have no known competing for financial interests or personal relationships".10

5

Doses reported in studies and on labels

No label for YK-11 was identified in DailyMed, and no study in people reporting a YK-11 dose was identified.

Table 5.1Doses reported in studies and on labels3 rows
SourceSpecies and nDose and routeDurationComparator
Harding and colleagues, 20239Two Thoroughbred horses50 mg per dose, oralThree daily dosesNone stated in the PubMed record
Dahleh and colleagues, 202310Male Wistar rats; group sizes not stated in the PubMed record0.35 g/kg; route not stated in the recordFive-week protocolControl group, exercise group and exercise plus YK11 group
Piper and colleagues, 20185Not stated in the PubMed recordSix-fold deuterated YK11; dose and route not stated in the recordNot statedNone stated

The app lists a typical dose of 5 to 15 mg per day by mouth, and none of the sources read reports a human dose of YK-11 to place beside it. The systematic review by Vasireddi and colleagues (American Journal of Sports Medicine, 2025) is about SARMs as a class; its record does not name YK-11, and it says "Athletes reported consuming SARMs at much higher doses than clinically studied".12

No adverse-event data from a trial of YK-11 in people were identified. The FDA reports that its testing of GE Labs Ykarine "was based on an adverse event report of a consumer who used the product and subsequently suffered a stroke".6 The product contained YK-11 as a listed ingredient and, in the FDA's testing, undeclared trendione, an anabolic steroid; the FDA states that anabolic steroids can cause serious liver injury and life-threatening reactions such as heart attack, stroke, pulmonary embolism, deep vein thrombosis and kidney damage.6 For SARMs in general, the FDA states that "Life-threatening reactions, including liver injuries that required hospitalization, have occurred in people taking products containing SARMs".6 It lists potential harms of SARMs including increased risk of heart attack or stroke, psychosis or hallucinations, sleep disturbances, sexual dysfunction, liver injury and acute liver failure, infertility, pregnancy miscarriage and testicular shrinkage.6 The FDA notes that such products "are often sold with no warnings on the labels".6

Vasireddi and colleagues (American Journal of Sports Medicine, 2025) reviewed 72 articles from 2003 to 2022 on SARMs as a class, with a stated level of evidence of 4.12 They report that SARM studies described "significant increases in lean body mass and side effects-including bone remodeling, testosterone suppression, and kidney, liver, and prostate enlargement".12 They add that most of the compounds athletes buy online "have been shown to be contaminated with other substances".12 The record names no individual SARM, so these class-level findings are not results for YK-11.12 In rats, YK11 was associated with increased oxidative stress and impaired mitochondrial function markers in the hippocampus, as described under the Dahleh analysis above.10 Lee and colleagues found YK-11 "not disclosed on the label" in some of 60 dietary supplements they tested, which bears on what a product contains.8 The app flags YK-11 as suppressive and hepatotoxic, and none of the YK-11 sources read measures hormone or liver results.

7

Bloodwork and markers

The app lists Total T, Lipids and Liver Enzymes as markers to monitor for YK-11. None of the sources read reports blood testosterone, lipid or liver enzyme results for YK-11 in people or animals. At class level, the Vasireddi review lists testosterone suppression among reported SARM side effects and hepatotoxicity among the consequences of SARM use.12 The FDA advises health professionals to be alert to liver injury, kidney injury, stroke and hormone-associated adverse effects in patients with signs of steroid or steroid-like substance use.6

The World Anti-Doping Agency's 2026 Prohibited List, in force from 1 January 2026, names YK-11 as an example of a SARM under S1.2 Other anabolic agents.1 Section S1 Anabolic agents is listed as prohibited at all times, in and out of competition, and states that "All prohibited substances in this class are non-Specified Substances".1 The S0 class of the same list covers any pharmacological substance "not addressed by any of the subsequent sections of the List" and with "no current approval by any governmental regulatory health authority for human therapeutic use"; YK-11 is named under S1.2.1 Piper and colleagues call YK11 "a non-approved substance for humans".5 The FDA states that bodybuilding products that often contain SARMs "are illegally marketed", that although generally marketed as dietary supplements they are not dietary supplements, and that they are unapproved drugs.6 No YK-11 label was identified in a DailyMed search, and the searches did not cover the European Medicines Agency or the Therapeutic Goods Administration.

9

What is not known

  • No half-life, bioavailability, time to peak or duration of action for YK-11 in people was identified, so the app's figures have no figure from a source beside them.
  • No dose-response, efficacy or safety trial of YK-11 in people was identified in PubMed or ClinicalTrials.gov.
  • The follistatin findings come from C2C12 cells, and the sources read report no measurement of myostatin in cells, animals or people.
  • The Piper elimination study does not state its participants, dose or route in the PubMed record, so the urinary findings cannot be tied to a dose.
  • Whether the rat findings of Dahleh and colleagues apply to people is not addressed by the sources; the authors call for further research on safety and efficacy in humans.
  • The one-compartment model the app uses for YK-11 is not supported by anything in the texts read.
What is the half-life of YK-11?

No half-life for YK-11 was identified in PubMed or ClinicalTrials.gov searches, and the app lists about 6 hours. In an elimination study, unconjugated urinary metabolites disappeared within 24 hours after administration, which is not a half-life.5

Is YK-11 banned by WADA?

The World Anti-Doping Agency's 2026 Prohibited List names YK-11 as an example of a SARM under S1.2 Other anabolic agents.1 The list states that anabolic agents are prohibited at all times, in and out of competition.1

Is YK-11 approved by the FDA?

The FDA describes bodybuilding products that often contain SARMs as not approved by the FDA.6 No YK-11 label was identified in a DailyMed search.

Is YK-11 a SARM or a steroid?

Thevis and colleagues call YK-11 "the steroidal SARM YK-11".4 Kanno and colleagues described it as "A novel steroid compound" and wrote that it "might act as selective androgen receptor modulator (SARM)".2

Does YK-11 inhibit myostatin?

In C2C12 cells, YK-11 induced follistatin expression, and the report does not mention myostatin.3 Piper and colleagues write that YK11 "is described to possess" myostatin inhibitor-like properties, and the sources read contain no myostatin measurement.5

Has YK-11 been tested in people?

No controlled trial of YK-11 in people was identified in PubMed or ClinicalTrials.gov. The studies identified involve cells, rats, horses or laboratory analysis, plus an elimination study whose participants the PubMed record does not state.5

What is the bioavailability of YK-11?

No oral bioavailability figure for YK-11 was identified, and the app lists 95%. In the elimination study with six-fold deuterated YK11, "no intact YK11 was observed" in the urine samples.5

What side effects of YK-11 have been reported?

No adverse-event data from a trial of YK-11 in people were identified. The FDA reports an adverse event of stroke in a consumer of a product, GE Labs Ykarine, that contained YK-11 as a listed ingredient and undeclared trendione.6 In rats, YK11 was associated with increased oxidative stress and impaired mitochondrial function markers in the hippocampus.10

How long are YK-11 metabolites detectable in urine?

In an elimination study with six-fold deuterated YK11, unconjugated metabolites disappeared within 24 hours after administration, and glucuronidated and sulfated metabolites were traceable for more than 48 hours.5 The PubMed record does not state the dose or the number of participants.

12

References

  1. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
  2. Kanno Y, et al. YK11 is a partial agonist of the androgen receptor. Biol Pharm Bull 2011. PMID 21372378
  3. Kanno Y, et al. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. Biol Pharm Bull 2013. PMID 23995658
  4. Thevis M, et al. Mass spectrometric characterization of the selective androgen receptor modulator (SARM) YK-11 for doping control purposes. Rapid Commun Mass Spectrom 2017. PMID 28440570
  5. Piper T, et al. Studies on the in vivo metabolism of the SARM YK11: identification and characterization of metabolites potentially useful for doping controls. Drug Test Anal 2018. PMID 30379415
  6. US Food and Drug Administration. Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more. Page current as of 2 December 2025. FDA page
  7. Yatsu T, et al. Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells. Biol Pharm Bull 2018. PMID 29491216
  8. Lee JH, et al. Development and validation of liquid chromatography-tandem mass spectrometry method for screening six selective androgen receptor modulators in dietary supplements. Food Addit Contam Part A 2021. PMID 33934684
  9. Harding C, et al. Equine metabolism of the selective androgen receptor modulator YK-11 in urine and plasma following oral administration. Drug Test Anal 2023. PMID 36519889
  10. Dahleh MMM, et al. YK11 induces oxidative stress and mitochondrial dysfunction in hippocampus: the interplay between a selective androgen receptor modulator (SARM) and exercise. J Steroid Biochem Mol Biol 2023. PMID 37468001
  11. Sobolevsky T, et al. Detection of selective androgen receptor modulator YK-11 in a doping control sample. Drug Test Anal 2024. PMID 37946705
  12. Vasireddi N, et al. Athlete Selective Androgen Receptor Modulators Abuse: A Systematic Review. Am J Sports Med 2025. PMID 39755947